Events2Join

AbCellera Biologics Inc.


AbCellera: Home

We have developed antibody discovery and development technologies to unlock high-value drug classes and targets, including T-cell engagers for cancer and ...

AbCellera Biologics Inc. (ABCL) Stock Price, News, Quote & History

Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing.

AbCellera - Wikipedia

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known ...

Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest ...

In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let's look at where AbCellera ...

AbCellera Biologics Inc (ABCL) Stock Price & News - Google Finance

Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more ...

AbCellera - LinkedIn

AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and ...

AbCellera Biologics Inc - Company Profile and News - Bloomberg

Company profile page for AbCellera Biologics Inc including stock price, company news, executives, board members, and contact information.

ABCL.O - | Stock Price & Latest News - Reuters

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine ...

AbCellera Biologics Inc. - Bill & Melinda Gates Foundation

Purpose: to identify potent anti-RSV monoclonal antibodies to protect infants in low and middle income countries from RSV infection morbidity and mortality.

AbCellera and Lilly broadens antibody discovery partnership

AbCellera focuses on discovering and creating antibody therapeutics for indications, including cancer, metabolic and endocrine problems, and ...

AbCellera Biologics, Inc. - Drug pipelines, Patents, Clinical trials

Explore AbCellera Biologics, Inc. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, 193 news, and 29 literature, ...

AbCellera Biologics Inc. (ABCL) Stock Price, Quote, News & Analysis

A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, ...

ABCL: Abcellera Biologics Inc - Stock Price, Quote and News - CNBC

Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

AbCellera Biologics Inc. Stock Quote (U.S. - ABCL - MarketWatch

AbCellera Biologics stock price target cut to $20 from $27 at Benchmark. Feb. 28, 2022 at 6:21 am ET by Tomi Kilgore.

AbCellera Biologics Inc. | Insights - Citeline

AbCellera Biologics Inc. https://abcellera.com/. Industry. Biotechnology. Drug Discovery Technologies. Genomics-Proteomics. Large Molecule. Antibodies. Gene ...

AbCellera Biologics Inc. - BioCentury Company Profiles - BCIQ

AbCellera Biologics Inc. ; Headquarters: Vancouver, BC, Canada · Year Founded: ; Industry Sector: HealthTechnology. CEO: ; Exchange/Ticker 1: NASDAQ:ABCL. Exchange/ ...

AbCellera Biologics Inc. - AnnualReports.com

AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from ...

ABCL | AbCellera Biologics Inc. Stock Overview (U.S.: Nasdaq)

Complete AbCellera Biologics Inc. stock information by Barron's. View real-time ABCL stock price and news, along with industry-best analysis.

AbCellera Biologics Inc. Common Shares (ABCL) - Nasdaq

Discover real-time AbCellera Biologics Inc. Common Shares (ABCL) stock prices, quotes, historical data, news, and Insights for informed trading and ...

NASDAQ:ABCL - AbCellera Biologics Inc. - TradingView

The current price of ABCL is 2.76 USD — it has decreased by −1.35% in the past 24 hours. Watch AbCellera Biologics Inc. stock price performance more closely on ...